Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference
March 05 2019 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that Sabrina Johnson, President and
Chief Executive Officer, will present at the Cowen 39th Annual
Healthcare Conference on Tuesday, March 12, 2019 at 8:40 a.m.
Eastern Time in Boston, MA. Ms. Johnson will present a Daré
overview and provide an update on the Company’s new late-stage
bacterial vaginosis program, DARE-BV1, a proprietary
solution-to-gel formulation containing clindamycin, an antibiotic
used to treat bacterial infections, as well as Daré’s mid-stage
programs: Ovaprene®, a potential first-in-class hormone-free
contraceptive solution; and Sildenafil Cream, 3.6%, a novel
vaginally delivered formulation of sildenafil, the active
ingredient in Viagra®, for the potential treatment of female sexual
arousal disorder (FSAD). Ms. Johnson will also review Daré’s
earlier stage programs, including DARE-HRT1, a potential first
combination vaginal ring that is designed to deliver both
bio-identical estradiol and bio-identical progesterone together
over 28 days to treat vasomotor symptoms (VMS) associated with
menopause as part of a hormone replacement therapy regimen.
The presentation will be webcast live and may be accessed by
visiting Daré’s website at http://ir.darebioscience.com. A replay
of the webcast will be available for 10 business days.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
sexual health, vaginal health, fertility, and contraception. The
company’s mission is to identify, develop and bring to market a
portfolio of novel, differentiated therapies that expand treatment
options, improve outcomes and facilitate convenience for women in
the areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential first-in-class
candidates in clinical development: Ovaprene®, a non-hormonal,
monthly contraceptive vaginal ring; and Sildenafil Cream, 3.6%, a
potential treatment for female sexual arousal disorder utilizing
the active ingredient in Viagra®, as well as a proprietary
solution-to-gel formulation of clindamycin to treat bacterial
vaginosis via a single application, DARE-BV1. To learn more about
Daré’s full portfolio of women’s health product candidates, and
mission to deliver novel therapies for women, please visit
www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website (http://ir.darebioscience.com), SEC
filings, press releases, public conference calls and webcasts.
Daré uses these channels to communicate with its investors
and the public about the company and other company-related matters.
The information Daré posts on its investor relations website may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts on its investor relations website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Alex GrayBurns
McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:Amanda GuisbondCanale
Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024